A universal droplet microfluidic platform for ultrahigh-throughput biocatalyst evolution

用于超高通量生物催化剂进化的通用液滴微流控平台

基本信息

批准号：
10705725
负责人：
Adam R. Abate
金额：
$ 81.71万
依托单位：
FLUID DISCOVERY INC
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-25 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10705725
关键词：
Abate Active Sites Amino Acids Architecture Automobile Driving Biological Biological Assay Biosensing Techniques Biotechnology Cannabinoids Capital Cells Chemicals Collaborations Complex Computational Technique Computer software Contracts Data Development Directed Molecular Evolution Engineering Environment Enzymes Evolution Feedback Funding Future Genetic Engineering Grant Health Human Industrialization Industry Label Laboratories Letters Libraries Liquid substance Manufacturer Marketing Mass Spectrum Analysis Materials Testing Mediation Metabolic Microfluidics Mission Mutagenesis Mutation Natural Products Nature Organism Outsourcing Pathway interactions Pharmacologic Substance Phase Phenotype Plastics Positioning Attribute Price Printing Privatization Production Property Recombinants Reporter Research Route Running Scheme Science Software Design Source Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization Structure Synthesis Chemistry Techniques Technology Testing Translating Variant Yarrowia lipolytica combinatorial commercialization computerized data processing cost cost effective design drug discovery enzyme activity gene synthesis innovation instrument manufacture manufacturing organization mutant nanolitre novel prototype research and development scale up screening success synthetic biology tool trend

项目摘要

Abstract The advance of biotechnology is dependent on approaches for rapidly iterating through genetically engineered enzymes and pathways. While computational and gene synthesis techniques have seen considerable innovation in the last few decades, screening variants for desired activities has lagged behind, with few notable advances. Indeed, microwell plates, a nearly 60-year-old technology, remain the dominant tool. The objective of Fluid Discovery is to transform this field by introducing a novel screening paradigm based on precision nanoliter fluid handling; this groundbreaking approach will increase the scale of screens that can be performed by 100x while driving down costs. In addition to a fundamentally new hardware architecture for scalable screening, our approach implements label-free mass spectrometry and computational techniques to enable discovery of unanticipated enzyme activities and enhancements. Fluid Discovery is founded by the inventor of the key technologies and, thus, is in a prime position to advance this space and become a commercial success. This grant will fuel the development of the first alpha prototype that can be run by early access customers, to illustrate the utility of the technology, its appropriateness for industrial research and development, and its maturity for the market; all of which will be necessary to raise private funding for commercial scale up. Our team includes experts in pharmaceutical development (Dr. Prince), commercialization (Dr. Sunkara), and science and technology (Dr. Abate). This team has a demonstrated track record of commercial success, having built companies with current value >$1 billion. Fluid Discovery’s technology will allow engineering campaigns infeasible with today’s technology at a price point accessible to biotech startups and academic research labs, and with transformative efficiencies attractive to Big Pharma.

抽象的生物技术的进步取决于基因工程快速迭代的方法而计算和基因合成技术已经取得了相当大的进展。过去几十年的创新，针对所需活动的筛选变体已经落后，几乎没有什么值得注意的事实上，微孔板这一已有近 60 年历史的技术仍然是主要的工具。 Fluid Discovery 的目标是通过引入基于精度的新型筛选范例来改变该领域纳升流体处理；这种突破性的方法将增加可进行的筛选规模 100 倍，同时降低成本，此外还有全新的可扩展硬件架构。筛选，我们的方法实施无标记质谱和计算技术，以实现 Fluid Discovery 的发明者发现了意想不到的酶活性和增强功能。关键技术，因此处于推进该领域并成为商业领域的首要地位这笔赠款将推动第一个可通过抢先体验运行的 alpha 原型的开发。客户，以说明该技术的实用性、其对工业研究的适用性和发展及其市场成熟度，所有这些都是筹集私人资金所必需的；我们的团队包括药物开发专家（Prince 博士），商业化（Sunkara 博士）和科学技术（Abate 博士）该团队拥有经过验证的轨道。 Fluid Discovery 的商业成功记录，其公司目前价值超过 10 亿美元。技术将使当今技术无法实现的工程活动以可承受的价格点实现生物技术初创公司和学术研究实验室，并具有对大型制药公司有吸引力的变革效率。